Ambroxol hydrochloride
[logo of the responsible entity]
This medicine should always be taken exactly as described in this patient leaflet or as directed by a doctor or pharmacist.
Ambroxol hydrochloride, the active substance of Mucosolvan, increases the secretion of mucus in the respiratory tract, making it easier to cough up and relieving cough.
Indications for use
Acute and chronic diseases of the lungs and bronchi with impaired mucus secretion and its transport.
If there is no improvement or the patient feels worse after 4 to 5 days, they should contact their doctor.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
Ambroxol increases the concentration of antibiotics (amoxicillin, cefuroxime, erythromycin) in bronchopulmonary secretions and sputum.
Mucosolvan should not be taken at the same time as cough medicines (e.g. codeine), as this may lead to a dangerous accumulation of bronchial secretions due to weakened cough reflex. Cough medicines, by inhibiting the cough reflex, make it difficult to cough up the thinned mucus.
No significant clinically relevant adverse interactions with other medicines have been found.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine.
Mucosolvan is not recommended during pregnancy, especially in the first three months of pregnancy.
Mucosolvan is not recommended for breastfeeding women, as ambroxol hydrochloride passes into breast milk.
There is no evidence that the medicine affects the ability to drive or operate machinery.
No studies have been conducted on the effect of the medicine on the ability to drive or operate machinery.
This medicine should always be taken exactly as described in this patient leaflet or as directed by a doctor or pharmacist.
In case of doubt, the patient should consult their doctor or pharmacist.
The recommended dose is:
Adults and children over 12 years old:
2 times a day, 10 ml of syrup
The recommended dose for acute respiratory infections and in the initial period of treatment for chronic conditions, for the first 14 days of treatment.
Children from 1 to 12 years old:
The above dosage is recommended for the initial treatment period; the dosage can be reduced by half after 14 days of treatment.
Mucosolvan syrup can be taken with or without food.
The medicine should not be taken before bedtime.
Patient age (years) | Dosage |
children 6 to 12 years old | 2 to 3 times a day, 5 ml of syrup |
children 2 to 6 years old | 3 times a day, 2.5 ml of syrup |
children 1 to 2 years old | 2 times a day, 2.5 ml of syrup |
The medicine should be measured using the enclosed measuring cup.
The medicine should not be given to children without consulting a doctor.
In case of taking a higher dose of Mucosolvan than recommended, the patient should consult their doctor or pharmacist.
No specific symptoms of overdose have been observed in humans to date. Based on cases of accidental overdose and/or reports of improper use, symptoms corresponding to the known side effects of the medicine at recommended doses have been observed, which may require symptomatic treatment.
If a dose is missed, it should be taken as soon as possible.
A double dose should not be taken to make up for a missed dose. The next dose should be taken at the usual time.
Mucosolvan should only be taken when necessary, and its use should be stopped after the symptoms have resolved.
In case of any further doubts about the use of this medicine, the patient should consult their doctor or pharmacist.
Like all medicines, Mucosolvan can cause side effects, although not everybody gets them.
If any side effects occur, including any side effects not listed in this leaflet, the patient should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department for Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw; tel: +48 22 492 13 01; fax: +48 22 492 13 09; website: https://smz.ezdrowie.gov.pl.
Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be gathered on the safety of the medicine.
There are no special precautions for storage.
The medicine should be stored out of sight and reach of children.
The medicine should not be used after the expiry date stated on the bottle and carton. The expiry date refers to the last day of the month.
The shelf life after first opening the package is 12 months.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Bottle made of orange glass type III with a PE cap with a guarantee ring and child-resistant closure, and a PP measuring cup with a scale for 1.25 ml, 2.5 ml, and 5 ml in a cardboard box.
1 bottle contains 100 ml or 200 ml of syrup.
Not all pack sizes may be marketed.
Marketing authorization holder:
Opella Healthcare Poland Sp. z o.o.
ul. Marcina Kasprzaka 6
01-211 Warsaw
Manufacturer:
Delpharm Reims
10 rue Colonel Charbonneaux
51100 Reims
France
To obtain more detailed information about this medicine, the patient should contact:
Opella Healthcare Poland Sp. z o.o.
ul. Marcina Kasprzaka 6
01-211 Warsaw
Tel.: +48 22 280 00 00
Date of last revision of the leaflet:April 2024
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.